Key facts
- This page summarizes John B. Payne's Form 4 filing for Zivo Bioscience, Inc. (ZIVO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jan 2026, 16:06.
John B. Payne - 26 Jan 2026 Form 4 Insider Report for Zivo Bioscience, Inc. (ZIVO)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ZIVO
- Reported as of
- 26 Jan 2026
- Net transaction value
- +$99,995
- SEC form
- 4
- Accepted by SEC
- 28 Jan 2026, 16:06:16 UTC
- Prior SEC filing
- 16 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John B. Payne
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John B. Payne filed Form 4 for Zivo Bioscience, Inc. (ZIVO) on 28 Jan 2026.
Change
- Previous filing in this sequence was filed on 16 Oct 2024.
- Current net transaction value: +$99,995.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001582392
Primary reporting owner
PAYNE JOHN BERNARD
- Relationship
- President and CEO, Director
- Address
- 2125 BUTTERFIELD DRIVE, SUITE 100, TROY
- Signature
- /s/ John B. Payne
- Signature date
- 28 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZIVO
transaction
Common Stock
Purchase
- Transaction value
- $99,995
- Shares
- +11,709
- Change %
- +148%
- Price
- $8.54
- Shares after
- 19,618
- Date
- 26 Jan 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.